BLDR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BLDR is not a good buy right now for a Beginner investor with a long-term focus and $50,000-$100,000 to deploy. The stock is weak technically, earnings momentum has deteriorated, and analyst targets have been cut sharply after the Q1 miss. While some Wall Street firms still see long-term housing-cycle upside, the current setup favors waiting rather than buying immediately.
The technical picture is bearish. MACD histogram is negative at -0.745 and still contracting, RSI_6 at 44.0 is neutral but below strong momentum levels, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 79.2 is below the pivot of 82.166 and near support at 75.175, indicating weak trend structure. The short-term pattern data also points lower, with downside probabilities over the next day, week, and month.
["Some analysts still believe Builders FirstSource is well positioned for an eventual housing recovery due to its scale and product breadth.", "Stabilization signs were noted in trusses and Engineered Wood Products.", "Share repurchases remain a near-term positive.", "Longer-term housing recovery optionality remains intact."]
["No major positive news in the recent week.", "Q1 results missed, with revenue down 10.13% YoY and net income turning negative.", "Gross margin fell 7.31% YoY, showing pressure on profitability.", "Housing backdrop remains weak, with inflationary pressure and competitive markets.", "Analysts broadly cut price targets after earnings, showing reduced near-term confidence.", "Congress trading shows 1 sale and 0 purchases, which leans cautious.", "Trading pattern analysis suggests near-term downside risk."]
In Q1 2026, Builders FirstSource showed deteriorating fundamentals. Revenue fell to $3.29B, down 10.13% year over year, net income dropped to -$47.4M, EPS fell to -0.43, and gross margin compressed to 28.26%. This is a weak latest-quarter seasonal print, indicating pressure on both growth and profitability rather than improving momentum.
Analyst sentiment is mixed but clearly more cautious after Q1. Price targets were cut across the board: BMO to $93, Deutsche Bank to $81, Truist to $115, Oppenheimer to $121, Baird to $95, UBS to $122, Raymond James to $100, KeyBanc to $100, Benchmark to $105, and Barclays to $93. The ratings are split between Hold/Market Perform/Neutral and Buy/Outperform/Overweight, but the broad direction is negative on targets. Wall Street pros see long-term value in the housing recovery and BLDR's scale, but the cons currently dominate: weak housing demand, margin pressure, revised guidance, and near-term earnings deterioration.
